Allison W Kurian

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Occurrence of breast cancer subtypes in adolescent and young adult women
    Theresa H M Keegan
    Cancer Prevention Institute of California, 2201 Walnut Ave, Suite 300, Fremont, CA 94538, USA
    Breast Cancer Res 14:R55. 2012
  2. pmc Performance of BRCA1/2 mutation prediction models in Asian Americans
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    J Clin Oncol 26:4752-8. 2008
  3. doi BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications
    Allison W Kurian
    Department of Medicine and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California 94305 5405, USA
    Curr Opin Obstet Gynecol 22:72-8. 2010
  4. pmc Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    Breast Cancer Res 12:R99. 2010
  5. ncbi A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    Allison W Kurian
    Department of Medicine, Division of Oncology, and the Veterans Affairs Palo Alto Health Care System and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA
    J Clin Oncol 25:634-41. 2007
  6. ncbi Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage
    Allison W Kurian
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5820, USA
    Health Expect 8:221-33. 2005
  7. ncbi Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk
    Allison W Kurian
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820
    Cancer Epidemiol Biomarkers Prev 14:1082-9. 2005
  8. pmc Online tool to guide decisions for BRCA1/2 mutation carriers
    Allison W Kurian
    Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 30:497-506. 2012
  9. ncbi Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma
    Anne Renee Hartman
    Department of Medicine, Stanford University School of Medicine, Stanford, California 94305 5458, USA
    Cancer 100:479-89. 2004
  10. pmc Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers
    Allison W Kurian
    Departments of Medicine, Health Research and Policy, and Radiology, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 28:222-31. 2010

Collaborators

Detail Information

Publications31

  1. pmc Occurrence of breast cancer subtypes in adolescent and young adult women
    Theresa H M Keegan
    Cancer Prevention Institute of California, 2201 Walnut Ave, Suite 300, Fremont, CA 94538, USA
    Breast Cancer Res 14:R55. 2012
    ....
  2. pmc Performance of BRCA1/2 mutation prediction models in Asian Americans
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    J Clin Oncol 26:4752-8. 2008
    ..We compared the performance in Asian and white individuals of two widely used BRCA1/2 mutation prediction models, BRCAPRO and Myriad II...
  3. doi BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications
    Allison W Kurian
    Department of Medicine and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California 94305 5405, USA
    Curr Opin Obstet Gynecol 22:72-8. 2010
    ..To summarize evidence on the prevalence and spectrum of BRCA1 and BRCA2 BRCA1/2 mutations across racial and ethnic groups and discuss implications for clinical practice...
  4. pmc Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    Breast Cancer Res 12:R99. 2010
    ....
  5. ncbi A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    Allison W Kurian
    Department of Medicine, Division of Oncology, and the Veterans Affairs Palo Alto Health Care System and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA
    J Clin Oncol 25:634-41. 2007
    ..We sought to evaluate the cost effectiveness of these regimens, which are expensive and potentially toxic...
  6. ncbi Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage
    Allison W Kurian
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5820, USA
    Health Expect 8:221-33. 2005
    ....
  7. ncbi Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk
    Allison W Kurian
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820
    Cancer Epidemiol Biomarkers Prev 14:1082-9. 2005
    ..Most publications on ductal lavage for cell collection report cannulating fluid-yielding ducts only. We report lavage of fluid-yielding and non-fluid-yielding ducts in women at high inherited breast cancer risk...
  8. pmc Online tool to guide decisions for BRCA1/2 mutation carriers
    Allison W Kurian
    Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 30:497-506. 2012
    ..A clinical decision tool could guide these complex choices...
  9. ncbi Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma
    Anne Renee Hartman
    Department of Medicine, Stanford University School of Medicine, Stanford, California 94305 5458, USA
    Cancer 100:479-89. 2004
    ....
  10. pmc Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers
    Allison W Kurian
    Departments of Medicine, Health Research and Policy, and Radiology, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 28:222-31. 2010
    ..We used decision analysis to simulate risk-reducing strategies in BRCA1/2 mutation carriers and to compare resulting survival probability and causes of death...
  11. doi Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers
    Elizabeth A Schackmann
    Departments of Medicine and of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    Fam Cancer 12:65-73. 2013
    ..50 and 4.69, on a 1-5 scale). Patients and health care providers rated the decision tool highly on measures of usability and clinical relevance. These results will guide a larger study of the tool's impact on clinical decisions...
  12. ncbi Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging
    Sylvia K Plevritis
    Department of Radiology, Division of Oncology, Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, Calif 94305, USA
    JAMA 295:2374-84. 2006
    ..Screening with contrast-enhanced breast magnetic resonance imaging (MRI) detects cancer earlier but increases costs and results in more false-positive scans...
  13. doi A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers
    Bronislava M Sigal
    Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cancer Epidemiol Biomarkers Prev 21:1066-77. 2012
    ..We estimate the impact of different risk-reducing options at various ages on life expectancy...
  14. ncbi Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers
    Ashley D Staton
    Department of Medicine, Stanford University School of Medicine, CCSR Building, Room 1115, 269 Campus Drive, Stanford, CA 94305 5151, USA
    Fam Cancer 7:179-86. 2008
    ..In order to explore women's preferences for management of elevated cancer risk, we evaluated the decisions of BRCA1/2 mutation carriers about contraception, prophylactic surgery, and family planning...
  15. ncbi Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage
    Pejman Ghanouni
    Department of Radiology, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Breast J 13:281-6. 2007
    ..Knowledge of the potential for breast MRI enhancement subsequent to DL, which can mimic the appearance of a pathologic lesion, is critical to the care of patients who undergo breast MRI and DL or other intraductal cannulation procedures...
  16. doi Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations
    Monique A de Bruin
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Fam Cancer 11:429-39. 2012
    ..Further investigation of racial differences in BRCA1/2 mutation epidemiology could inform targeted cancer risk-reduction strategies...
  17. pmc Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry
    Allison W Kurian
    Stanford University School of Medicine, Department of Health Research and Policy, Stanford, CA 94305 5405, USA
    Cancer Epidemiol Biomarkers Prev 18:1084-91. 2009
    ..Two widely used models, BRCAPRO and BOADICEA, were developed using data from non-Hispanic Whites (NHW), but their accuracies have not been evaluated in other racial/ethnic populations...
  18. pmc Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry
    Allison W Kurian
    Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Oncol 29:4505-9. 2011
    ..We estimated breast cancer risks for noncarriers by using a population-based sample of patients with breast cancer and their female first-degree relatives (FDRs)...
  19. pmc Breast cancer treatment across health care systems: Linking electronic medical records and state registry data to enable outcomes research
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Palo Alto, California Department of Health Research and Policy, Stanford University School of Medicine, Palo Alto, California
    Cancer 120:103-11. 2014
    ..In the current study, the authors analyzed the information yielded by integrating breast cancer data from 3 sources: electronic medical records (EMRs) from 2 health care systems and the state registry...
  20. ncbi A young woman with bilateral breast cancer: identifying a genetic cause and implications for management
    Monique A de Bruin
    Department of aMedicine, Stanford University School of Medicine, Stanford, California 94305 5405, USA
    J Natl Compr Canc Netw 11:512-7. 2013
    ..Given the specialized counseling and testing needs of patients with Li-Fraumeni syndrome, and the implications for targeted screening strategies if a mutation is found, referral to a cancer genetics expert is strongly recommended...
  21. ncbi The decline in breast cancer incidence: real or imaginary?
    Allison W Kurian
    Stanford University School of Medicine, Stanford, CA 94305, USA
    Curr Oncol Rep 11:21-8. 2009
    ..However, significant controversy remains as to the timing, causes, generalizability, and longevity of this reported decline in incidence...
  22. pmc Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Breast Cancer Res Treat 137:247-60. 2013
    ..72, 95 % CI 1.02-2.90). In this equal-access healthcare system, chemotherapy use followed practice guidelines, but varied by race and socio-demographic factors. These findings may inform efforts to optimize quality in breast cancer care...
  23. doi Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
    Melinda L Telli
    Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Breast Cancer Res Treat 127:471-8. 2011
    ..Given the poor prognosis and high treatment costs of HER2-positive breast cancer, our results have implications for healthcare resource utilization, cancer biology, and clinical care...
  24. pmc CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer
    Jeffrey A Norton
    Department of Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94035, USA
    Ann Surg 245:873-9. 2007
    ....
  25. pmc Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines
    Ashley A Powell
    Department of Surgery, Stanford University School of Medicine, Stanford, California, USA
    PLoS ONE 7:e33788. 2012
    ..Here we demonstrate feasibility of performing high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery...
  26. pmc Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research
    Susan C Weber
    Center for Clinical Informatics, Stanford University, USA
    AMIA Annu Symp Proc 2012:970-8. 2012
    ..Through our efforts using these methods, Oncoshare integrates complex, longitudinal data from multiple electronic medical records and registries and provides a rich, validated resource for research on oncology care...
  27. doi A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
    Shaveta Vinayak
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Breast Cancer Res Treat 142:389-98. 2013
    ..The results are inconclusive and do not exclude a favorable effect on breast cancer risk. ..
  28. doi The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival
    Anna H Wu
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Rm 4443, Los Angeles, CA, 90089, USA
    Cancer Causes Control 24:1821-36. 2013
    ..This cohort will enable analyses to jointly consider a variety of clinical, lifestyle, and contextual factors in attempting to explain the long-standing disparities in breast cancer outcomes...
  29. ncbi Histologic types of epithelial ovarian cancer: have they different risk factors?
    Allison W Kurian
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820, USA
    Gynecol Oncol 96:520-30. 2005
    ..The goals of the current study were to characterize further the relation of histologic-specific ovarian cancer risks to reproductive and lifestyle attributes...
  30. ncbi A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature
    Pavandeep Ghataorhe
    School of Medicine, Oxford University, South Parks Road, Oxford OX1 3PL, UK
    Cancer Genet Cytogenet 179:89-92. 2007
    ..To our knowledge, this is the first report of a patient with both MEN1 and BRCA2 mutations and with a personal history of hyperparathyroidism and pancreatic neuroendocrine tumors...
  31. doi Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytology
    Allison W Kurian
    Breast J 14:211-4. 2008